FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

Mar 19, 2019

Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

Feb 26, 2019

Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

Feb 25, 2019

Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

Feb 5, 2019

Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

Jan 23, 2019

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Jan 7, 2019

Cellectar Biosciences to Present at the Biotech Showcase

Jan 3, 2019

Cellectar Granted Japanese Patent for CLR 131

Dec 11, 2018

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

Dec 4, 2018

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 13, 2018